Table 3.
Studies reporting mortality due to HK in patients receiving HD (n = 12).
| Author, year, country | Population | Study period | Subgroup (N) | Age (years)a, % male | S-K+ levels (mmol/L) | Follow-up (months) | Death due to HK |
|---|---|---|---|---|---|---|---|
| Balle et al. 1990, Germany | ESRF due to analgesic-associated nephropathy | 1970–1986 | Total population (55) | 61 (44–79), 34.5% | NR | 57 | 7.3% |
| Chaaban et al. 2013, United Arab Emirates | CKD | NR | Control group (30) | 48.9 (18.7), 52% | NR | 3 | 0% |
| Charytan et al. 2017, USA | ESRD | NR | Placebo (51) | NR | > 6.0 | 8.3 | 0% |
| Jadoul et al. 2012, International | ESRD | 1996–2008 | Total population (37,765) | NR | > 5.0 | 19.1a | 1.3% |
| Li et al. 2012, China | ESRD | 2006–2011 | Total population (268) | NR | NR | 60 | 4.5% |
| Li et al. 2020, China | CKD | 2011–2015 | Total population (210) | 56.6 (16.6), 59.5% | NR | 49.8b | 4.4% |
| Lomonte et al. 2004, Italy | ESRD/Leprosy | 1980–2003 | Total population (8) | 61 (8.9), 75% | NR | NR | 12.5% |
| Morduchowicz et al. 1992, Israel | ESRF | NR | Total population (84) | NR | NR | 66 | 5% |
| Onuigbo et al. 2013, Italy | ESRD | 2007–2010 | Total population (466) | 65.6 (19–97)b, 49.1% | NR | 28.9a | 3% |
| Poulikakos et al. 2015, UK | Renal failure | NR | Total population (75) | 60 (14), 68% | NR | 35.9a | 1.3% |
| Pun et al. 2012, USA | ESRD | 2002–2005 | Total population (363) | 69 (59–78)b, 55.4% | NR | NR | 1.3% |
| Shibata et al. 1983, Japan | Renal failure | NR | Total population (62) | 50 (26–78), 67.7% | NR | NR | 3.2% |
CKD: chronic kidney disease; ESRD: end-stage renal disease; ESRF: end-stage renal failure; HK: hyperkalemia; NR: not reported; S-K+: serum potassium.
aMean (SD) or mean (range).
bMedian (IQR).